Form 4: Lixte Biotechnology Director Stephen Forman Reports Stock Option Grants
SEC Form 4
Director Stephen Forman reports the grant of stock options in Lixte Biotechnology Holdings, Inc.
Summary
- Stephen Forman, a director of Lixte Biotechnology Holdings, Inc., filed a Form 4 detailing changes in his beneficial ownership.
- On June 30, 2024, Forman was granted options to purchase 10,000 shares of common stock at an exercise price of $2.37, vesting quarterly starting September 30, 2024.
- Additionally, Forman received options to purchase 3,018 shares of common stock at $2.37, vesting immediately, in lieu of quarterly cash compensation.
- Forman also holds other options and warrants to purchase common stock at various prices and expiration dates.
Sentiment
Score: 6
Explanation: The document is a routine disclosure of stock option grants. It's neutral in tone and doesn't contain any overtly positive or negative information.
Positives
- The grant of options to a director may align his interests with those of shareholders.
- The immediate vesting of 3,018 shares in lieu of cash compensation could conserve company cash.
Industry Context
Stock option grants are a common form of compensation for directors and executives in publicly traded companies, aligning their interests with those of shareholders.
Stakeholder Impact
- The stock option grants could potentially dilute existing shareholders if the options are exercised.
Key Dates
| Date | Description |
|---|---|
| 12/07/2018 | Date of warrants to purchase common stock |
| 05/22/2019 | Date of options to purchase common stock |
| 01/06/2021 | Date of options to purchase common stock |
| 06/30/2021 | Date of options to purchase common stock |
| 10/16/2017 | Date of options to purchase common stock |
| 06/30/2022 | Date of options to purchase common stock |
| 12/07/2022 | Expiration date of warrants to purchase common stock |
| 05/22/2024 | Expiration date of options to purchase common stock |
| 06/30/2023 | Date of options to purchase common stock |
| 06/30/2024 | Date of stock option grants and earliest transaction |
| 06/30/2026 | Expiration date of options to purchase common stock |
| 01/06/2026 | Expiration date of options to purchase common stock |
| 06/30/2027 | Expiration date of options to purchase common stock |
| 06/30/2028 | Expiration date of options to purchase common stock |
| 06/30/2029 | Expiration date of options to purchase common stock |
| 09/30/2024 | Vesting start date for 10,000 share options |
| 07/02/2024 | Date of signature |
Keywords
Form 4, Stock Options, Beneficial Ownership, LIXT, Lixte Biotechnology, Stephen Forman, Director
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.